Industry Explorers Blaze On
Industry Explorers Blaze On is a series of interviews with senior executives who played a historical role in drug discovery and development and are still active in the biopharma industry.
Industry Explorers Blaze On: Anna Protopapas
Her mother was the first woman of her village in Cyprus to go to high school. Anna Protopapas shared her mother’s drive to bypass all barriers, and she now runs the biopharma company Mersana, after many years in the leadership of Millennium and Takeda.
Industry Explorers Blaze On: Pat Andrews
A look at the 26-year career of Pat Andrews, CEO of Boston Biomedical, who went from Big Pharma to small biotech.
Industry Explorers Blaze On: Deborah Dunsire
Deborah Dunsire has lived and worked in a world driven by commercial drug development for three decades. She’s worked for Big Pharmas such as Novartis and Sandoz and is now trying her hand at managing a small pharma as president & CEO of XTuit. For sure, she’s been a pioneer — but she’s not done yet.
Industry Explorers Blaze On: Leading Business With Science — Part 2
We continue the story of Geert Cauwenbergh whose nearly 40 years in the industry included work with Paul Janssen as well as being a startup entrepreneur with RXi Pharmaceuticals.
Leading Business With Science: Geert Cauwenbergh of RXi
Geert Cauwenbergh now can look back at his almost four decades in the industry — from his formative years working with Paul Janssen building a small company into a global phenomenon, to his later years as a startup entrepreneur with RXi — and reflect on how most of it has turned upon a snap decision.
Abbey Meyers: Did The Pioneer Of Orphan Drugs Spark Biopharma?
By the time Abbey Meyers, founder of the National Organization for Rare Disorders (NORD) and chief architect of the ODA, wrote her letter to me a few years later, the paradoxical conflict of orphan-drug availability versus price had become obvious.
David Hale: How The Journey To Entrepreneurial Biotech Begins
These are the stories of longtime leaders, still active in the industry, sharing their historical perspectives on innovation in the life sciences industry. This month: Why David Hale is considered an icon of entrepreneurial biotech.
Industry Explorers Blaze On: R&D Veteran William Comer Of NeuroGenetic
The chairman of Bristol-Myers summoned the head of R&D into his office. “Bill, go down and check out the ruckus on the street,” he said. “Something about our new AIDS drug.” When Dr. William Comer exited the front door of the company’s New York City headquarters, he saw a small group of men marching around on the sidewalk, holding signs, blowing trumpets, beating drums, and chanting loudly.
BEYOND THE PRINTED PAGE
Communicating Authentically During Times Of Crisis4/19/2021
John Fowler, cofounder and CEO of Kezar Life Sciences, shares “A Letter to Kezar Employees,” a best practice example of a leader communicating authentically and transparently during times of crisis (i.e., the killing of George Floyd).
A Lesson Learned The Hard Way4/18/2021
Neil Kumar, cofounder and CEO of BridgeBio, discusses his rationale behind why employees didn’t have titles during the startup phase.
BridgeBio’s Neil Kumar Remembers Those Humble Beginnings4/12/2021
Neil Kumar, cofounder and CEO of BridgeBio, a company today valued at more than $10 billion, shares an embarrassing experience of the startup’s humble beginnings.
LIFE SCIENCE LEADER BLOGS
Disruption of life routines by COVID-19 provide a CNS opportunity on multiple fronts.
While biopharma's response to COVID-19 has started to turnaround the industry's sagging reputation, one successful response to one crisis does not a reputation save.